Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product consists of SVN-114 for the treatment of post-traumatic stress disorder; and SVN-015 for the treatment of stimulant use disorder. The company was formerly known as Graft Polymer (UK) Plc and changed its name to Solvonis Therapeutics plc in January 2025. Solvonis Therapeutics plc was incorporated in 2017 and is headquartered in London, the United Kingdom.…
Solvonis Announces Result of AGM
Solvonis Therapeutics (LON: SVNS) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 6 employees.
The shares were at 0.0850 GBp on 20 November 2026, down 64.6% over 52 weeks. Its 52-week range is 0.0750 GBp to 0.3340 GBp: the price is 74.6% below the high and 13.3% above the low.
Its market capitalisation is 6.71M GBP.
Solvonis Therapeutics reports return on equity of -92.7% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 587.00K GBP. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.
No upcoming events tracked.